SAFETY, TOLERANCE, AND PHARMACOKINETICS OF SYSTEMIC RIBAVIRIN IN CHILDREN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION

被引:58
作者
CONNOR, E
MORRISON, S
LANE, J
OLESKE, J
SONKE, RL
CONNOR, J
机构
[1] CHILDRENS HOSP NEW JERSEY, DEPT PEDIAT, NEWARK, NJ 07103 USA
[2] UNIV CALIF SAN DIEGO, SAN DIEGO MED CTR, DEPT PHARM, SAN DIEGO, CA 92103 USA
[3] UNIV CALIF SAN FRANCISCO, SCH PHARM, SAN FRANCISCO, CA 94143 USA
[4] UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA
关键词
D O I
10.1128/AAC.37.3.532
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations. The children tolerated the drug well, and treatment was not associated with any clinically significant adverse effects. Peak concentrations in plasma of 2.5 and 3.0 muM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively. The mean systemic availability of oral ribavirin was 42.3%. After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 muM were obtained. Ribavirin penetrated well into the cerebrospinal fluid, achieving 70% of the concentration in plasma at steady state.
引用
收藏
页码:532 / 539
页数:8
相关论文
共 37 条
[1]   SENSITIVE RADIOIMMUNOASSAY FOR THE BROAD-SPECTRUM ANTIVIRAL AGENT RIBAVIRIN [J].
AUSTIN, RK ;
TREFTS, PE ;
HINTZ, M ;
CONNOR, JD ;
KAGNOFF, MF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (05) :696-701
[2]   RIBAVIRIN ANTAGONIZES INHIBITORY EFFECTS OF PYRIMIDINE 2',3'-DIDEOXYNUCLEOSIDES BUT ENHANCES INHIBITORY EFFECTS OF PURINE 2',3'-DIDEOXYNUCLEOSIDES ON REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS INVITRO [J].
BABA, M ;
PAUWELS, R ;
BALZARINI, J ;
HERDEWIJN, P ;
DECLERCQ, E ;
DESMYTER, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1613-1617
[3]  
BALZARINI J, 1990, J ACQ IMMUN DEF SYND, V3, P1140
[4]   POTENTIATING EFFECT OF RIBAVIRIN ON THE ANTIRETROVIRUS ACTIVITY OF 3'-AZIDO-2,6-DIAMINOPURINE-2',3'-DIDEOXYRIBOSIDE INVITRO AND INVIVO [J].
BALZARINI, J ;
HERDEWIJN, P ;
DECLERCQ, E .
ANTIVIRAL RESEARCH, 1989, 11 (04) :161-172
[5]  
BODSWORTH N, 1990, J ACQ IMMUN DEF SYND, V3, P893
[6]   STATISTICAL ESTIMATIONS IN PHARMACOKINETICS [J].
BOXENBAU.HG ;
RIEGELMA.S ;
ELASHOFF, RM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (02) :123-148
[7]   RESPIRATORY SYNCYTIAL VIRUS-INFECTION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTED CHILDREN [J].
CHANDWANI, S ;
BORKOWSKY, W ;
KRASINSKI, K ;
LAWRENCE, R ;
WELLIVER, R .
JOURNAL OF PEDIATRICS, 1990, 117 (02) :251-254
[8]  
CHECK IJ, 1972, MANUAL CLIN LABORATO
[9]   RIBAVIRIN TREATMENT OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) AND THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME-RELATED COMPLEX (ARC) - A PHASE-1 STUDY SHOWS TRANSIENT CLINICAL IMPROVEMENT ASSOCIATED WITH SUPPRESSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS AND ENHANCED LYMPHOCYTE-PROLIFERATION [J].
CRUMPACKER, C ;
HEAGY, W ;
BUBLEY, G ;
MONROE, JE ;
FINBERG, R ;
HUSSEY, S ;
SCHNIPPER, L ;
LUCEY, D ;
LEE, TH ;
MCLANE, MF ;
ESSEX, M ;
MULDER, C .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (05) :664-674
[10]  
CRUMPACKER C, 1986, LANCET, V2, P45